Oura Shares Key Financials and Regulatory Developments Ahead of IPO
Oura, a wearable ring company planning an initial public offering (IPO), has revealed key financial details in its prospectus. The firm reported significant growth, with net income rising from $1.6 million to $60.8 million over the past year and revenue increasing steadily since fiscal year 2024. Oura's product pricing ranges between $349 and $499 for hardware, supported by a monthly subscription fee of $5.99. The company is also advancing into regulated medical features through an FDA-approved blood pressure study involving over 350,000 participants. While most current functions fall under the wellness exemption, Oura plans to introduce tools that may require regulatory approval as medical devices in the future. The firm's expansion includes partnerships with companies like Dexcom and Resmed. Oura has sold 3.1 million rings this fiscal year and now counts over 5 million paid members, driven largely by a high conversion rate of customers who purchase hardware before subscribing to its services.
Topics: FDA regulation IPO medical devices wearable technology